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Background: Plants remain an important source of new drugs, new leads and new chemical entities. Triptolide is a
diterpenoid epoxide isolated from Tripterygium wilfordii Hook F that possesses a broad range of bioactivities,
including anti-inflammatory, immunosuppressive and anti-tumor properties. The antiviral activity of triptolide against
human immunodeficiency virus type 1 (HIV-1) has not been reported.
Results: In this study, nanomolar concentrations of triptolide were shown to potently inhibit HIV-1 replication in vitro.
To identify the step(s) of the HIV-1 replication cycle affected by triptolide, time-of-addition studies, PCR analysis and
direct transfection of viral genomic DNA were performed. The results of these experiments indicated that triptolide acts
at the stage of viral gene transcription. In addition, a luciferase-based reporter assay that allows quantitative analysis of
long terminal repeat (LTR)-driven transcription showed that Tat-induced LTR activation was impaired in the presence of
triptolide. Moreover, Western blot analysis of exogenous gene expression (driven by the human elongation factor 1 α
subunit promoter) in transiently transfected cells revealed that triptolide specifically reduces the steady-state level of Tat
protein, without suppressing global gene expression. Further studies showed that triptolide accelerates Tat protein
degradation, which can be rescued by administration of the proteasome inhibitor MG132. Mutation analysis revealed that
N-terminal domains of Tat protein and nuclear localization are required for triptolide to reduce steady-state level of Tat.
Conclusion: This study suggests for the first time that triptolide exerts its anti-HIV-1 activity by specifically prompting the
degradation of the virally encoded Tat protein, which is a novel mechanism of action for an anti-HIV-1 compound. This
compound may serve as a starting point for developing a novel HIV-1 therapeutic approach or as a basic research tool for
interrogating events during viral replication.
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The current therapeutic strategy for the treatment of hu-
man immunodeficiency virus type 1 (HIV-1) infection and
acquired immune deficiency syndrome (AIDS) is highly ac-
tive antiretroviral therapy (HAART) [1]. Although HAART
have been shown to be successful in controlling viral repli-
cation and disease progression, issues of multidrug resist-
ance, side effects and poor compliance continue to raise
concerns [2-4]. Furthermore, given the presence of
long-lived latently infected cells, the current HAART
formula does not eradicate the virus even after a* Correspondence: chenxl@wh.iov.cn
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unless otherwise stated.prolonged period of treatment [5]. Thus, discovery and
development of novel therapies for the treatment of
HIV-1 infection is still needed.
HIV-1 gene transcription is an essential step in the viral
life cycle and the only stage during which viral genome
amplification occurs. HIV-1 transcription is predomin-
antly directed by a promoter in the 5′ long terminal repeat
(5′ LTR) of the integrated provirus and is regulated by
viral regulatory proteins as well as cellular factors [6]. The
virally encoded Tat protein is essential for efficient tran-
scription and plays a central role in sustaining a high level
viral replication [7,8]. Tat protein directly binds to the
trans-activating response element (TAR), an RNA stem-
loop structure located at the 5′ ends of nascent HIV-1
transcripts. In binding to TAR, Tat recruits a positiveral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of cyclin T1 (CycT1) and cyclin-dependent kinase 9
(CDK9) [9,10]. Subsequently, CDK9 phosphorylates the
C-terminal domain of RNA polymerase II and thus en-
hances transcription elongation [11]. The transcriptional
machinery, which depends upon the intricate interplay be-
tween the viral regulatory protein Tat and various host
components, represents a potential therapeutic target that
has not been exploited by currently available antiretroviral
drugs [12]. Up to this point, intensive research efforts have
focused on the discovery and development of selective
HIV-1 replication inhibitors targeting Tat-mediated tran-
scription. These inhibitors include the Tat/TAR/ P-TEFb
interaction inhibitors and molecules that interfere with
host factors [13-22]. However, none of these inhibitors
have advanced to clinical trials because of their potential
toxicity, despite extensive research.
Tripterygium wilfordii Hook F is a Chinese herd with
an established history of use in the treatment of rheumatoid
arthritis. Triptolide is a diterpenoid epoxide isolated from
Tripterygium wilfordii Hook F with a broad range of bioac-
tivities, including anti-inflammatory, immunosuppressive
and anti-tumor properties [23]. In this study, triptolide was
found to potently inhibit HIV-1 replication at nanomolar
concentrations. In a manner distinct from all previously de-
scribed HIV-1 transcription inhibitors, mode-of-action
studies have demonstrated that triptolide specifically en-
hances Tat protein degradation, resulting in suppression of
LTR-mediated viral gene transcription.
Results
Triptolide inhibits HIV-1 replication in vitro
In an effort to identify novel anti-HIV-1 inhibitors, more
than 200 highly purified natural compounds were
screened using TZM-bl cells and replication competent
HIV-1 (NL4-3 strain). TZM-bl cells are permissive to
HIV-1 infection and harbor an integrated copy of the lu-
ciferase gene under transcriptional control of the HIV-1
5′ LTR promoter. Reporter gene expression is induced
by viral Tat protein upon infection. Thus, compounds
targeting any stage from viral entry to viral gene expres-
sion can be detected in this assay. The cytotoxicity of
the tested compounds was also evaluated in parallel with
the antiviral assay. For each compound, the concentra-
tion which inhibits luciferase expression by 50% (EC50)
and the concentration which reduces cell viability by
50% (CC50) were calculated using logistic regression ana-
lysis. As shown in Figure 1A and B, among all the com-
pounds screened, triptolide showed the highest selective
index (SI, the ratio of CC50 to EC50). Following primary
screening, the antiviral activity of triptolide was evalu-
ated in a panel of in vitro cell-based assays.
We first confirmed the antiviral activity of triptolide in
the TZM-bl assay. As shown in Figure 2A, a significantand dose-dependent inhibitory effect on virus replication
was observed at concentrations in the nanomolar range
(EC50 = 0.32 nM). At 5 nM, the compound reduced lu-
ciferase expression by 97.9%. To exclude the possibility
that the inhibitory effect was due to nonspecific cytotox-
icity, cell viability assays were performed in parallel, and
no obvious toxicity was observed at all tested concentra-
tions (Figure 2A).
Considering that the TZM-bl assay monitors the
stages of infection up to the integration of viral cDNA
into the host cell chromosome and the expression of
viral gene, we presume that this compound may act at
any stage from viral entry to viral gene expression. Next,
the antiviral activity of triptolide was validated in Jurkat
T lymphocytes using a single-cycle HIV-1 reporter virus
(replication defective pNL4-3.Luc.E-R- packaged with an
HIV-1 NL4-3 envelope). Upon integration into the host
chromosome, this recombinant virus expresses the firefly
luciferase gene, and consequently, luciferase activity in in-
fected cells correlates with the rate of viral replication.
Thus, compounds targeting any stage from viral entry to
viral gene expression should be active in this assay. Consist-
ent with our observations in the TZM-bl assay, triptolide
treatment inhibited virus replication in a dose-dependent
manner, with an EC50 of 0.45 nM (Figure 2B).
To further characterize its anti-HIV-1 activity, triptolide
was evaluated in the p24 assay using peripheral blood
mononuclear cells (PBMCs) as host cells. As shown in
Figure 2C and D, the level of HIV-1 NL4-3 replication was
significantly reduced in the presence of triptolide as mea-
sured by p24 production. At the maximum non-toxic con-
centration (4 nM), triptolide reduced p24 level by 89.4 to
99.1%, depending on the time of detection. Furthermore,
triptolide also showed similar potency against two other
HIV-1 strains, LAI and BaL, in PBMCs from different do-
nors (See the summary of antiviral data in Table 1). Col-
lectively, these results demonstrate that triptolide inhibits
acute HIV-1 infection in various cell types.
Triptolide inhibits HIV-1 gene transcription
After confirmation of the anti-HIV-1 activity of triptolide,
we sought to identify its mechanism of action. To pinpoint
the stage targeted by triptolide during viral replication,
time-of-addition experiment was performed. TZM-bl cells
were infected with HIV-1 NL4-3, and triptolide and refer-
ence compounds were added to the infected cells at vari-
ous time points. Viral replication level was quantified at
48 h post-infection by measuring luciferase activity. The
inhibition profile of tirptolide was compared to the pro-
files of reference compounds with a known mechanism of
action. As shown in Figure 3A, the viral entry inhibitor
dextran sulfate showed a dramatic early loss in activity.
However, the reverse-transcription inhibitor zidovudine
retained significant inhibitory activity (71%) when added
Figure 2 Triptolide potently inhibits HIV-1 replication in vitro. (A) The effect of triptolide on HIV-1 replication in TZM-bl reporter cells. TZM-bl
cells were infected with HIV-1 (MOI = 0.5, strain NL4-3) in the presence of 3-fold serial dilutions of triptolide. Virus replication was quantified by
measuring luciferase expression at 48 h post-infection. A cell viability assay was carried out in parallel using CellTiter-Glo. (B) The effect of triptolide on
HIV-1 reporter virus replication in Jurkat cells. Jurkat cells were infected with HIV-1-Luc (pNL4-3.Luc.R-E- pseudotyped with the NL4-3 envelope) at an
MOI of 0.5 in the presence of triptolide. Luciferase gene expression was quantified at 48 h post-infection. Compound cytotoxicity was determined in
mock-infected cells. (C) Cytotoxicity of triptolide in PBMCs. PBMCs from donor A were treated with the indicated concentrations of triptolide for six
days before cell viability examination using CellTiter-Glo. (D) Inhibition of HIV-1 replication in PBMCs. PBMCs from donor A were infected with HIV-1
(MOI = 0.01, strain NL4-3) in the presence of increasing concentrations of triptolide. Supernatants were collected at the indicated days post-infection
and virus replication levels were determined using p24 ELISA. Results were presented as the mean plus the standard deviations (n = 3).
Figure 1 Screen of natural compounds led to the identification of triptolide as a novel anti-HIV-1 agent. (A) TZM-bl cells were infected
with HIV-1 NL4.3 at an MOI of 0.5 in the presence of serially diluted test compounds. Virus replication was quantified by measuring luciferase
expression at 48 h post-infection. The cytotoxicity of the tested compounds was evaluated in parallel with their antiviral assays. The anti-HIV-1
activity of each compound was presented as selective index, the ratio of CC50 to EC50. (B) Chemical structure of triptolide.
Wan and Chen Retrovirology 2014, 11:88 Page 3 of 13
http://www.retrovirology.com/content/11/1/88
Table 1 In vitro anti-HIV-1 activity of triptolide
Virus Cell type Measurement EC50 (nM)
a CC50 (nM)
b SIc
HIV-1 NL4-3 TZM-bl Luciferase 0.32 25.4 79.4
HIV-1-Luc Jurkat Luciferase 0.45 13.9 30.9
HIV-1 NL4-3 PBMC donor A p24 1.1d 12.6 11.5
HIV-1 NL4-3 PBMC donor B p24 0.9d 15.3 17.0
HIV-1 NL4-3 PBMC donor C p24 1.3d 11.2 8.6
HIV-1 LAI PBMC donor A p24 1.5d 12.6 8.4
HIV-1 LAI PBMC donor B p24 1.2d 15.3 12.8
HIV-1 LAI PBMC donor C p24 1.5d 11.2 7.5
HIV-1 BaL PBMC donor A p24 1.4d 12.6 9.0
HIV-1 BaL PBMC donor B p24 1.6d 15.3 9.6
HIV-1 BaL PBMC donor C p24 1.0d 11.2 11.2
aCompound concentration required to reduce the production of luciferase or p24 antigen by 50%.
bCompound concentration required to reduce mock-infected cell viability by 50%.
cSelective index, ratio of CC50/EC50.
dEC50 value was calculated based on p24 inhibition at day 6 post-infection.
Figure 3 Triptolide inhibits HIV-1 transcription. (A) Time-of-addition analysis. TZM-bl cells were infected with HIV-1 (MOI = 0.5, strain NL4-3), and the
virus inoculum was removed after 1 h of absorption. Test compounds (dextran sulfate at 10 μg/mL, zidovudine at 1 μM and triptolide at 5 nM) were added
at the indicated time points after infection. Reporter signal was monitored at 48 h post-infection as a measure of viral replication. (B) The effect of triptolide
on HIV-1 proviral DNA formation. Jurkat cells were infected with HIV-1 (MOI = 0.5, strain NL4-3) in the presence of the test compounds (INI 118-D-24,
50 μM; flavopiridol, 20 nM; and triptolide, 5 nM). Proviral DNA synthesis was determined by nested PCR analysis at 12 h post-infection. (C) The effect of
triptolide on HIV-1 mRNA synthesis. Jurkat cells were infected with HIV-1(MOI = 0.5, strain NL4-3) in the presence of the test compounds (INI 118-D-24,
50 μM; flavopiridol, 20 nM; triptolide, 5 nM). Viral mRNA (the Gag region) content was determined by reverse-transcription PCR analysis 12 h post-infection.
(D) Inhibition of luciferase expression encoded in pNL4-3.Luc.R-E- by tiptolide. HIV-1 molecular clone pNL4-3.Luc.R-E- and pRL-TK (transfection efficiency
control) were co-transfected into Jurkat cells. Transfected cells were cultured in the presence of the test compounds (INI 118-D-24, 50 μM; flavopiridol, 20
nM; triptolide, 0.2 ~ 5 nM) for an additional 24 h before measuring luciferase activity with a dual-luciferase assay system. Results were presented as the
mean plus the standard deviations (n= 3).
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http://www.retrovirology.com/content/11/1/88up to 4 h post-infection and lost its activity thereafter. In
contrast, triptolide displayed a profile that was distinct
from both references. Addition of triptolide could be post-
poned up to 10 h post-infection without losing activity,
suggesting that this compound affects a stage that is post
reverse-transcription.
The post-reverse-transcription events of the viral repli-
cation cycle include integration and gene expression. To
elucidate the effect of triptolide on these two events, syn-
thesis of proviral DNA and viral mRNA during single-
round infection was examined by PCR analysis. Jurkat
cells were infected with wild-type HIV-1 in the presence
of triptolide and reference compounds, and total DNA
and mRNA were extracted 12 h post-infection (the use of
this early time point ruled out de novo infection) for the
examination of integrated proviral DNA and viral mRNA.
As shown in Figure 3B and C, the integrase inhibitor 118-
D-24 [24] reduced proviral DNA formation and subse-
quent viral mRNA synthesis. However, triptolide along
with the HIV-1 gene transcription inhibitor flavopiridol
[16] had no effect on virus integration but did repress viral
mRNA synthesis, suggesting that triptolide inhibits HIV-1
transcription from integrated proviral DNA.
To further confirm that triptolide interferes with HIV-
1 transcription, a transient gene expression assay was
performed. The HIV-1 molecular clone pNL4-3.Luc.E-R-
was transfected into Jurkat cells in the presence of either
triptolide or various reference compounds. At 24 h after
transfection, viral gene transcription (indicated by lucif-
erase activity) was determined. In this assay, the early
events during viral replication, including entry, reverse
transcription and integration were bypassed, and the dir-
ect effect of the test compounds on viral gene expression
was examined. As expected, the integrase inhibitor 118-
D-24 was inactive in the assay, and the gene expression
inhibitor flavopiridol significantly reduced luciferase ex-
pression (Figure 3D). Interestingly, triptolide inhibited
reporter expression in a dose-dependent manner with a
potency comparable to levels observed in the antiviral
assays, further suggesting that this compound acts at the
stage of viral gene transcription.
Triptolide inhibits Tat-mediated gene transcription
Among the viral and cellular factors involved in HIV-1
gene transcription, the viral protein Tat and the NF-κB/
Rel family of cellular transcription factors are the most
important factors for LTR-mediated viral gene transcrip-
tion. The promoter-proximal region of HIV-1 LTR con-
tains two adjacent NF-κB binding sites. Upon a variety
of stimuli (e.g. TNF-α) and cell activation, NF-κB can
bind to LTR and activates HIV-1 transcription. To gain
further insight into the mechanism of action of tripto-
lide, this compound was examined for its direct effect
on Tat and NF-κB-mediated HIV-1 gene transcriptionusing reporter assays. As shown in Figure 4A and B,
transfection with the Tat expression plasmid or treat-
ment with 10 ng/mL TNF-α induced approximately 145-
or 2.8-fold increase in luciferase activity in TZM-bl cells
respectively. Under these conditions, triptolide reduced
Tat-induced reporter activity in a dose-dependent fash-
ion. Interestingly, triptolide appeared to slightly enhance
TNF-α-induced luciferase production in TZM-bl cells.
In another system using Jurkat cells, the inhibitory ef-
fect of triptolide on Tat-induced gene expression was
confirmed using a co-transfection experiment with an
HIV-1 LTR-driven luciferase plasmid and the Tat expres-
sion plasmid (Figure 4C). Triptolide had no effect on
TNF-α induced gene expression at the tested concentra-
tions in Jurkat cells (Figure 4D). In addition, triptolide
also reduced the Tat-mediated LTR activation in Jurkat
cells transfected with the HIV-1 LTR containing two
mutated NF-κB binding sites (Figure 4C), demonstrating
that inhibition by triptolide is independent of the NF-κB
signaling pathway. In both TZM-bl and Jurkat cells, trip-
tolide did not affect basal LTR transcription activity at
the tested concentrations (Data not shown). Collectively,
these results suggest that triptolide inhibits Tat-mediated
HIV-1 LTR-driven transcription.Triptolide specifically reduces steady-state level of
Tat protein
In theory, triptolide may exert its activity through
interfering with Tat protein expression or Tat function
or both. Thus, we next investigated whether triptolide
directly affects Tat protein expression level by trans-
fecting HeLa cells with plasmid expressing FLAG-
tagged Tat (the human elongation factor 1 α subunit
promoter, EF1 α promoter). Strikingly, the steady-state
level of Tat protein was reduced by triptolide in a dose-
dependent manner as was determined with Western
blotting (Figure 5A). Inhibition on Tat protein expres-
sion was a selective event and was not accompanied by
the global suppression of cellular gene expression,
since the expression levels of endogenous cyclin T1
and CDK9 remained unchanged in the presence of
triptolide (Figure 5A). To exclude the possibility that
triptolide acts against the transcription activity of EF1
α subunit promoter, we also constructed the plasmids
expressing green fluorescent protein (GFP) and Tat-
GFP fusion protein. The expression level of GFP was
not reduced in the presence of triptolide (Figure 5B).
However, this compound reduced the steady-state
levels of Tat-GFP dose-dependently, indicating this
compound does not affect the EF1α subunit promoter
activity and specifically targets Tat protein. Taken to-
gether, these data strongly suggest that triptolide spe-
cifically reduces the steady-state level of Tat protein.
Figure 4 Triptolide inhibits Tat-mediated LTR activation. (A) TZM-bl cells were co-transfected with pEF1-Tat and pRL-TK, and treated with the
test compounds. Luciferase activity was measured at 48 h post-transfection. (B)TZM-bl cells were treated with TNF-α (10 ng/mL) in the presence
of the test compounds, and luciferase activity was measured at 24 h post-transfection. (C) Jurkat cells were co-transfected with pLTR-Luc or
pLTRΔκB-Luc, pEF1-Tat and pRL-TK in the presence of the test compounds. Luciferase activity was measured 48 h post-transfection. (D) Jurkat
cells were co-transfected with pGL3-LTR and pRL-TK in the presence of the test compounds. TNF-α (10 ng/mL) was added 36 h post-transfection.
Luciferase activity was measured 48 h post-transfection. Pyrrolidine dithiocarbamate (PDTC) at 100 μM and flavopiridol at 20 nM were used as
positive controls. Results were presented as the mean plus the standard deviations (n = 3).
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proteasomal degradation of Tat
To investigate whether triptolide decreases Tat protein
levels by reducing its mRNA stability, we transfected HeLa
cells with the Tat expression plasmid and assessed the
steady-state mRNA level of Tat in the presence or absence
of triptolide using reverse-transcription PCR analysis. Not-
ably, treatment with triptolide did not significantly alter
Tat mRNA abundance (Figure 6A), indicating that this
compound does not alter the stability of Tat mRNA but
rather exerts its activity on later processes, such as mRNA
translation or protein degradation.Figure 5 Triptolide specifically reduces steady-state level of Tat prote
of increasing concentrations of triptolide. Cells were harvested 48 h post-tr
blotting. (B) HeLa cells were transfected either with pEF1-GFP (left) or pEF1
triptolide. Cells were harvested 48 h post-transfection, and protein expressiTherefore, we next performed protein translation arrest
experiments to investigate whether triptolide reduces Tat
stability. HeLa cells expressing FLAG-Tat were pretreated
with triptolide or DMSO for 28 h, cycloheximide (CHX)
was then administrated. Cells were harvested in a time
course. Western blotting results showed that FLAG-Tat
was degraded more quickly upon the treatment of tripto-
lide (Figure 6B). To calculate the half-lives of FLAG-Tat,
the natural log values of band intensities were plotted
against time (Figure 6C). The half-life of FLAG-Tat was
determined to be 2.0 h, and it was reduced to 0.4 h in the
presence of triptolide. Overall, these results showed thatin. (A) HeLa cells were transfected with pEF1-FLAG-Tat in the presence
ansfection, and protein expression levels were determined by Western
-Tat-GFP (right) in the presence of increasing concentrations of
on levels were determined by Western blotting.
Figure 6 Triptolide reduces Tat protein stability by enhancing proteasomal degradation of Tat. (A) The effect of triptolide on Tat mRNA levels.
HeLa cells were transfected with pEF1-Tat in the presence of increasing concentrations of triptolide. Cells were harvested 48 h post-transfection. The
steady-state mRNA levels of Tat and GAPDH were examined using semi-quantitative reverse transcription PCR analysis. RT, reverse transcriptase. (B) The
effect of triptolide on Tat protein degradation. HeLa cells were transfected with pEF1-FLAG-Tat in the presence of 5 nM triptolide or vehicle (DMSO). At
28 h post-transfection, cells were treated with 20 μg/mL of CHX to arrest protein synthesis. At 0, 1, 2, 3 h post-treatment, cells were harvested to
determine protein expression levels using Western blot analysis. (C) The band intensities of FLAG-Tat in panel B were measured, and their natural log
values were plotted as a function of time. Results were presented as the mean plus the standard deviations (n = 3). (D) Proteasome inhibition restores
Tat protein expression. HeLa cells were transfected with pEF1-FLAG-Tat in the presence or absence of 5 nM triptolide. At 48 h post-transfection, cells were
treated with 20 μM of MG132, and cultured for an additional 3 h before harvest. Protein expression levels were determined by Western blot analysis.
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protein stability.
Tat degradation is regulated by proteasomal systems
[25]. Theoretically, if triptolide enhances Tat protein
degradation, inhibition of proteasomal degradation
[26,27] could rescue the decreased Tat expression caused
by triptolide. HeLa cells expressing FLAG-Tat in the
presence or absence of triptolide were treated with the
proteasomal inhibitor MG132 before probing with West-
ern blotting. As shown in Figure 6D, MG132 treatment
increased Tat level by 30%, indicating the amount of de
novo synthesized Tat protein was approximately 30% of
the content in DMSO control. In the presence of tripto-
lide, Tat protein expression was reduced to undetectable
level and restoration of Tat protein was observed after
treatment with MG132 (also increased by 30% of Tat
level in DMSO control). Thus, in the presence of
MG132, the activity of triptolide on newly synthesized
Tat protein was completely abolished. These data taken
together suggest that triptolide specifically reduces Tat
protein steady-state levels by enhancing proteasomal
degradation of Tat protein.
N-terminal domains of Tat are required for triptolide to
reduce Tat steady-state levels
To further understand the mode-of-action of triptolide
to induce Tat degradation, we tried to map the regions
of Tat protein that confer the sensitivity to triptolide.Deletion mutants in six domains were generated in a
plasmid expressing an N-terminal FLAG tag in a man-
ner that encompassed the entire length of NL4-3 Tat
protein (Figure 7A). HeLa cells were transfected with
one of the domain deletion mutants, and the protein ex-
pression levels in the absence or presence of triptolide
were assessed (Figure 7B). Results showed that the N-
terminal regions, including acidic region, cysteine region
and core region, are absolutely required, since the deletion
of one of these regions completely aborted the activity of
triptolide (Figure 7B). In contrast, the C-terminal regions
(amino acid residues 58–86) are dispensable, and the po-
tency of triptolide against these mutants was similar to
that against wild-type Tat (Figure 7B). Interestingly, the ef-
fect of triptolide was partially attenuated with the deletion
of basic region, indicating that basic region is also involved
in the mode-of-action of triptolide (Figure 7B).
Tat basic domain contains two arginine methylation
sites and a nuclear localization signal (NLS). Previous
studies showed that arginine methylation in the basic do-
main increases the stability of Tat, and the posttransla-
tional modification occurs in the cell nucleus [28]. So we
generated two FLAG-Tat mutants to study the involve-
ment of arginine methylation and nuclear localization in
triptolide’s mode-of-action. In the first mutant (FLAG-
Tat-SFV), the basic domain was replaced with the NLS
from Semliki Forest virus (SFV) capsid protein (without
arginine residues, Figure 7C) [29]. In the other mutant,
Figure 7 N-terminal domains are required for triptolide to reduce Tat steady-state levels. (A) Schematic diagram of domains of HIV-1 Tat.
(B) The effects of triptolide on steady-state levels of Tat mutants. HeLa cells were transfected with plasmids encoding truncated forms of Tat in
the presence of increasing concentrations of triptolide. Cells were harvested 48 h post-transfection, and protein expression levels were determined by
Western blotting. (C) Schematic diagram of wild-type Tat and two mutants with domain substitution. In Tat-SFV, the basic domain was replaced with
NLS from SFV capsid. In Tat-NES, the NES from HIV-1 Rev was fused to the C-terminus of Tat. (D) The effects of triptolide on steady-state levels of Tat
mutants depicted in panel C. HeLa cells were transfected with plasmids encoding Tat mutants in the presence of increasing concentrations of tritpolide.
Cells were harvested 48 h post-transfection, and protein expression levels were determined by Western blotting. (E) HeLa cells were transfected with
pEF1-FLAG-Tat or pEF1-FLAG-TatΔ49–57 in the presence or absence of 5 nM triptolide. At 48 h post transfection, the nucleus and cytoplasm were
fractionated using NE-PER nuclear and cytoplasmic extraction reagent, and protein expression levels were determined by Western blotting. C, cytoplasm;
N, nucleus. (F) HeLa cells were transfected with pEF1-Tat49–57-GFP in the presence of increasing concentrations of triptolide. Cells were harvested 48 h
post-transfection, and protein expression levels were determined by Western blotting.
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nal (NES) from HIV-1 Rev [30] was fused to the C-
terminus of Tat (Figure 7C). HeLa cells were transfected
with either wild-type FLAG-Tat, or one of the mutants in
the presence of different concentrations of triptolide to as-
sess the effect of these mutations on triptolide mediated
degradation of Tat. Strikingly, the steady levels of FLAG-
Tat-NES remained unchanged despite the presence of an
intact basic region, indicating nuclear localization of Tat is
critical (Figure 7D). In sharp contrast to FLAG-Tat-NES,
FLAG-Tat-SFV expression was dose-dependently reduced
by triptolide (Figure 7D), suggesting arginine methylation
is not required. Based on these data, we conclude that nu-
clear localization of Tat, but not arginine methylation, is
required for triptolide to reduce Tat steady-state levels.
To further confirm that nuclear localization is required
for triptolide’s action, the nuclear/cytoplasmic protein sep-
aration assay was performed. As shown is Figure 7E, the
wild-type Tat protein predominantly localized to the nu-
cleus. With basic domain deleted, Tat protein (TatΔ49–57)
could localize to both cytoplasm and nucleus (Figure 7E).
In such conditions, triptolide only acted on Tat protein ac-
cumulated in nucleus, but not Tat protein accumulated in
cytoplasm (Figure 7E). These observations explained why
triptolide was partially active against basic domain-deleted
Tat mutant (Figure 7B). Next, we tested triptolide’s activity
on the fusion protein of Tat basic domain with GFP
(Tat49–57-GFP). The results indicated that basic domain
alone was not sufficient to mediate the susceptibility to
triptolide (Figure 7F). Taken together, N-terminal domains
of Tat (amino acid residues 1–57) are required for tripto-
lide to reduce Tat steady-state levels.
Discussion
Although the advent of HAART changed the landscape
of HIV/AIDS, there is still no cure for this disease cur-
rently available. Therefore, the discovery and develop-
ment of novel therapeutics for HIV infection is still
necessary. In this study, we found that triptolide inhib-
ited HIV-1 replication by prompting Tat protein degrad-
ation, a novel mechanism of action. This compound was
identified as a novel HIV-1 replication inhibitor in a
cell-based assay using TZM-bl cells. Other in vitro anti-
viral assays demonstrated that this compound also spe-
cifically inhibits HIV-1 replication in the Jurkat T cell
line and in PBMCs (Figure 2). After the validation of anti-
viral activity, we performed time-of-addition experiments
and PCR analysis to determine the step(s) affected by this
compound. The results of these experiments demon-
strated that triptolide acts at a post-integration step and
blocks viral gene transcription (Figure 3). Further study
showed that triptolide can reduce Tat-induced LTR activa-
tion, confirming the conclusion that this compound tar-
gets viral gene transcription (Figure 4). Interestingly,treatment with triptolide led to a reduction of steady-state
levels of Tat protein in transient transfection systems. The
suppression of Tat expression was specific, because the ex-
pression of GFP using the same vector was not affected.
More importantly, the expression levels of tested cellular
genes, which are essential for LTR transcription activity,
were not impaired (Figure 5). PCR analysis of cells trans-
fected with the Tat expressing plasmid revealed that Tat
mRNA level remained unchanged upon treatment. How-
ever, proteasomal inhibition rescued down-regulated Tat
protein expression, indicating that triptolide acts at the
stage of Tat protein degradation (Figure 6). These data
taken together suggest that triptolide interferes with Tat
protein degradation and thus blocks acute HIV-1 infection
at the stage of viral transcription. Considering that Tat-
mediated viral transcription is a common event in all
forms of HIV-1 replication, triptolide is also expected to
inhibit virus production from chronically and latently in-
fected cells. Further studies should be performed to deter-
mine whether triptolide also provides therapeutic benefits
in chronic and latent infection systems.
Control of HIV-1 gene transcription is an attractive
approach for anti-HIV-1 chemotherapy. However, at-
tempts to repress viral transcription present several
unique challenges, because most factors involved in
HIV-1 transcription are host general transcriptional
regulators and cofactors, that are required for host gene
expression. For example, although compounds targeting
P-TEFb and other factors have been shown to block
HIV gene expression, these compounds have a global
impact on cellular gene expression and thus lack speci-
ficity. Therefore, the clinical potential of compounds
that targeting the host transcription machinery is very
limited due to safety concerns.
Although triptolide has been reported to possess mul-
tiple bioactivities that interfere with host transcriptional
factors at higher concentrations, none of the activities
were responsible for the unique antiviral profile ob-
served in this study. In previous studies, triptolide was
found to interfere with TNF-α-induced NF-κB activation
[31]. The cellular factor NF-κB is a potent activator of
HIV-1gene transcription, and many NF-κB inhibitors
have been reported to block viral gene expression and
replication [32]. However, the highest concentration we
used in our assays was only 5 nM, which was not active
against TNF-α-induced LTR activation in our reporter
assay (Figure 4B and D). Furthermore, triptolide showed
comparable potency against Tat-induced LTR and
LTRΔκB activation (Figure 4C). Taken together, these re-
sults showed that the antiviral activity of triptolide could
not be attributed to NF-κB inhibition. In other reports,
triptolide was shown to inhibit global gene transcription
by inducing the degradation of RNA polymerase II [33],
and inhibiting the ATPase activity of XPB, a subunit of
Wan and Chen Retrovirology 2014, 11:88 Page 10 of 13
http://www.retrovirology.com/content/11/1/88the general transcription factor TFIIH [34]. These results
may raise the concern that triptolide blocks Tat protein
expression by nonspecific disruption of the cellular tran-
scription machinery. However, several lines of evidence
should relieve this concern. First, this compound pos-
sessed a therapeutic window in all cell-based assays
tested. Second, the expression levels of exogenous gene
(GFP, in the same vector) and several endogenous genes
tested are not affected by triptolide in the transient
transfection assay (Figure 5A and B). Third, the basal
transcriptional activity of HIV-1 LTR, which is regulated
by a large number of host transcriptional activators
[35,36], remained unchanged in the presence of tripto-
lide (Data not shown). Thus, these results indicated that
triptolide specifically targets Tat protein, without effect
on global cellular gene expression.
To further understand the mechanism, we also per-
formed mutation studies and identified N-terminal do-
mains of Tat and nuclear localization are essential for
the action of triptolide (Figure 7). Although the molecu-
lar details of Tat degradation caused by triptolide remain
unclear, the specific and unique mode of action warrants
further investigation. Posttranslational modification of Tat
protein was reported to regulate Tat protein stability [29].
Although we have demonstrated that arginine methylation
in basic region is not required for triptolide to prompt Tat
degradation, we cannot rule out the possibility that tripto-
lide may interfere with other forms of post-translational
modification in its N-terminal domains, and thus reduces
Tat stability. Other reports indicated that interaction be-
tween Tat and its partners can stabilize Tat expression
levels [37,38]. This raises an alternative possibility that
triptolide disrupts the interaction between Tat and its sta-
bilizers and sensitize Tat to degradation. Further studies
should be performed to determine the exact mechanism
based on these hypotheses.
As mentioned above, several previous studies have in-
dicated that triptolide may interfere with important cel-
lular functions at higher doses [31,33,34,39-41]. This
property may be the reason why triptolide exhibited a
limited therapeutic window (SI = 7.5 ~ 79.4, depending
on the cell type and virus strain) in our in vitro antiviral
assays. Thus, despite the novel mode of action, the clin-
ical potential of triptolide in its current form may still be
limited due to potential safety concerns. In this regard,
synthetic chemistry studies should be performed to ex-
plore the structure activity relationship (SAR) of triptolide,
define the chemical groups responsible for its antiviral ac-
tivity, and test whether other unwanted bioactivities could
be eliminated through chemical modification. Potentially,
potent derivatives of triptolide that avoid undesired activ-
ities may be developed. Of course, it is also a possible that
the chemical nature of triptolide makes it unsuitable for
further drug development.Conclusion
Our results presented here demonstrate that triptolide
inhibits HIV-1gene transcription and replication by
prompting proteasomal degradation of Tat protein, a
novel anti-HIV-1 mechanism. Although the therapeutic
utility of triptolide in its current form may be limited due
to safety concerns, triptolide may serve as a starting point
for developing novel HIV-1 therapeutic approaches or as a
basic research tool for interrogating events during viral
replication.
Methods
Cell culture, plasmids and viruses
HeLa, 293 T and Jurkat cells were obtained from American
Type Culture Collection (ATCC). TZM-bl cells (catalog
no.8129) and MT-4 cells (catalog no.120) were obtained
through the NIH AIDS Research and Reference Reagent
Program (National Institute of Allergy and Infectious Dis-
eases). PBMCs were isolated from healthy donors by using
Ficoll-Paque PREMIUM (GE Healthcare) according to
the manufacturer’s instructions. HeLa and TZM-bl cells
were propagated in Dulbecco’s modified Eagle’s medium
(DMEM) (Invitrogen) supplemented with 10% FBS
(Gibco), 100U/mL of penicillin and 0.1 mg/mL of strepto-
mycin. Jurkat cells, MT-4 cells and PBMCs were grown in
RPMI 1640 supplemented with 10% FBS and 10 μg/mL of
gentamicin.
The HIV-1 molecular clone pNL4-3 (catalog no.114),
pLAI.2 (catalog no.2532) and the env-deficient proviral
clone pNL4-3.Luc.R-E- (catalog no.3418) were obtained
through the AIDS Research and Reference Reagent Pro-
gram. HIV-1 Tat expression plasmid pEF1-Tat, pEF1-
FLAG-Tat were generated by cloning the full-length Tat
coding sequence (containing both exon 1 and exon 2) of
HIV-1 NL4-3 or FLAG-Tat into pEF1-V5/His-A (Invi-
trogen), respectively. FLAG-Tat mutants expressing plas-
mids were constructed by standard molecular cloning
methods. pGL3-Basic and pRT-TK were purchased from
Promega. pLTR-Luc was constructed by inserting the
HIV-1 NL4-3 5′ LTR region (1 ~ 789) into pGL3-Basic.
pLTRΔκB-Luc was constructed by deleting two NF-κB
binding sites from pLTR-Luc.
The HIV-1 strains NL4-3 and LAI were generated by
transfecting the corresponding plasmids into 293 T cells
and propagating them in MT-4 cells. The HIV-1 strain BaL
was kindly provided by Dr. Qinxue Hu (Wuhan Institutes
of Virology, Chinese Academy of Sciences). The single-
round reporter virus HIV-1-Luc was generated by co-
transfecting 293 T cells with pNL4.3R-E-Luc and the
plasmid expressing the HIV-1 NL4-3 envelope protein.
Antibodies and compounds
The anti-FLAG antibody (F1804) was purchased from
Sigma-Aldrich. Antibodies to Glyceraldehyde-3-phosphate
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(#2555), cyclin T1 (#8744) and CDK9 (#2316) were pur-
chased from Cell Signaling Technology. The anti-Lamin B
antibody (SC-374015) was purchased from Santa Cruz
Biotechnology. All horseradish peroxidase labeled second-
ary antibodies were obtained from Thermo Scientific.
The compounds isolated from Chinese traditional herbs
for the anti-HIV-1 drug screen were purchased from
Sichuan Weikeqi Biological Technology Co., Ltd., China.
The purity of the compound was ≥ 98%, as was deter-
mined by high-performance liquid chromatography ana-
lysis. The compound samples were solved in dimethyl
sulfoxide (DMSO) at a concentration of 50 mM. The fol-
lowing reference compounds were obtained through the
NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH: zidovudine (catalog no.
3485), integrase inhibitor 118-D-24 (catalog no. 9957) and
(−) flavopiridol (catalog no. 9925). Dextran sulfate sodium
salt (average molecule weight of 5,000 Da), PDTC, MG132
and CHX were purchased from Sigma-Aldrich.
In vitro anti-HIV-1 assays
The anti-HIV-1 activities of compounds were evaluated
in a variety of assays, including the TZM-bl assay, re-
porter virus assay, and PBMCs-based antiviral assay. In
the TZM-bl assay, TZM-bl cells were plated at a density
of 1 × 104 cells per well in 96-well tissue culture plates
one day before infection. On the day of the experiment,
the cell supernatant was removed, and 100 μL of each
serially diluted compounds was added were added. HIV-
1 NL4-3 in 50 μL of complete medium was then added
to each well to achieve a multiplicity of infection (MOI)
of 0.5. At 48 h post-infection, the luciferase activity in
the cells was analyzed with the SteadyGlo reagent (Pro-
mega) according to manufacturer’s instructions. The lu-
minescent signal was measured using the EnVison 2102
Multilabel Reader (Perkin Elmer). The EC50 (50% effective
concentration) values correspond to compound concentra-
tions that resulted in a 50% reduction in luciferase activity.
In the antiviral assay with the HIV-1 reporter virus,
Jurkat cells were seeded at a density of 2 × 104 cells per
well in 96-well tissue culture plates and infected with
HIV-1-Luc at an MOI of 0.5 in the presence or absence
of the test compounds. At 48 h post-infection, luciferase
activity in the cells was determined and EC50 values
were calculated as described above.
In the antiviral assay using PBMCs, determination of
the anti-HIV-1 activity of a particular compound was
based on the inhibition of HIV-1 capsid protein (p24)
production. After isolation, PBMCs were stimulated with
phytohemagglutinin (2 μg/ml, Sigma-Aldrich) and
interleukin-2 (20 U/mL, Sigma-Aldrich) in RPMI 1640
complete medium for three days and were then main-
tained with interleukin-2 during viral infection. PBMCswere infected with HIV-1 NL4-3 (MOI = 0.01). After viral
adsorption for 2 h, the cells were washed thoroughly with
culture medium to remove unabsorbed viral particles. The
infected cells (2 × 105 cells/well) were cultured in 96-well
plates in the presence of or absence of the test compound.
At two, four, six, and eight days post-infection, half of the
culture supernatant was collected and replaced with fresh
medium containing the test compounds. The level of viral
replication was determined with an HIV-1 p24 antigen
capture enzyme-linked immunosorbent assay (ELISA).
The EC50 values corresponded to compound concentra-
tions that resulted in a 50% reduction in p24 production
at day 6 post-infection.
The cytotoxicity of the tested compounds was evalu-
ated in parallel with their antiviral assays using the
CellTiter-Glo reagent (Promega) according to the manu-
facturer’s protocol. The 50% cytotoxic concentrations
(CC50s) is the compound concentration that reduced cell
viability by 50%.Time-of-addition experiment
TZM-bl cells seeded in 96-well plates (2 × 104 /well)
were infected with HIV-1 NL4-3 (MOI = 1). The virus
inoculum was removed after 1 h of infection. Test com-
pounds were added at different time points after infec-
tion (0 h, 2 h, 4 h, 6 h, 8 h, and 10 h). Dextran sulfate
was added at 10 μg/mL, zidovudine at 1 μM and tripto-
lide at 5 nM. At 48 h post-infection, the virus replication
level was determined by analyzing luciferase activity in
the cells as described above.Semi-quantitative PCR analysis
The effects of the test compounds on HIV-1 proviral
DNA and mRNA synthesis were analyzed by PCR. Jurkat
cells were grown in 24-well plates and infected with the
HIV-1 NL4-3 strain at an MOI of 0.5, and then test
compounds were added at the desired concentrations.
After incubation for 12 h, genomic DNA and mRNA
from the infected cells were isolated using a Genomic
DNA Mini Preparation Kit (Beyotime, China) and TRI-
zol reagent (Invitrogen Life Technologies), respectively.
Nested PCR was used for the amplification of integrated
proviral DNA, as previously described [42]. To deter-
mine viral mRNA expression levels, 1 μg of RNA was
treated with RQ1 RNase-Free DNase (Promega) and re-
verse transcribed using M-MLV Reverse Transcriptase
(Promega) and random primers (Promega). An aliquot of
cDNA was used as template for amplification of the HIV-
1 Gag region as described elsewhere [43]. As DNA and
RNA input controls, genomic DNA and cDNA was sub-
jected to GAPDH amplification using the primers 5′-G
AAGGTGAAGGTCGGAGTC-3′ and 5′-GAAGATGGTG
ATGGGATTTC-3′.
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particular compound on Tat mRNA expression. Sub-
confluent HeLa cells were grown in 24-well plates and
transfected with pEF1-Tat in the absence or the presence
of the test compounds. Total mRNA was extracted at
48 h post-transfection, and reverse transcription was per-
formed as described above. Then, the cDNA was subjected
to Tat gene amplification using the primers 5′- GAAGC
ATCCAGGAAGTCAGCC -3′ and 5′-ACAAACTTGGC
AATGAAAGCAACAC-3′. GAPDH was used as an input
control.
All of the PCR products were visualized on a UV
transilluminator in 2% agarose gels stained with eth-
idium bromide. In preliminary experiments, the expo-
nential range of the PCR amplification curve was
determined for all of the PCR products by varying the
amount of input DNA and the number of PCR cycles.
Based on these experiments, appropriate conditions
were chosen to perform semi-quantitative PCRs.
HIV-1 LTR-luciferase reporter assay
The effect of the test compounds on HIV-1 LTR pro-
moter activity was evaluated using the luciferase reporter
systems in both TZM-bl and Jurkat cells. TZM-bl cells
seeded in 96-well plates (2 × 104 cells/well) were treated
with either 10 ng/mL TNF-α (Sigma-Aldrich) or co-
transfected with pEF1-Tat and pRL-TK (for transfection
efficiency normalization) using Lipofectamine 2000
(Invitrogen). The cells were then cultured in the presence
of various concentrations of the test compounds. After
24 h (TNF-α stimulation) or 48 h (Tat transfection) of in-
cubation, luciferase activity was determined from cell ly-
sates using the StedyGlo reagent (for TNF-α treated cells)
or a dual luciferase assay system (Promega, for transfected
cells) as recommended by the manufacturer.
Jurkat cells were seeded in 24-well plates at a density of
2 × 105 cells per well. For TNF-α induction, cells were co-
transfected with pLTR-Luc and pRL-TK in the presence
or absence of the test compounds. Then, the cells were
treated with 10 ng/mLTNF-α 36 h post-transfection. After
induction for an additional 12 h, luciferase activity was an-
alyzed. For Tat-induced LTR activation, Jurkat cells were
co-transfected with pLTR-Luc (or pLTR-Luc-ΔkB), pEF1-
Tat and pRL-TK, and cultured in the presence of various
concentrations of test compounds for an additional 48 h
before the determination of luciferase activity. Luciferase
levels were expressed relative to levels in cells without
induction.
Western blot analysis
Cells in 12-well plates were transfected using Lipofecta-
mine 2000 and treated as indicated in figure legends.
Cells were washed with phosphate buffered saline (PBS)
and lysed with radio immunoprecipitation assay lysisbuffer supplemented with complete mini protease in-
hibitor cocktail (Roche) at 4°C for 1 h. Proteins from cell
lysates were separated by SDS-PAGE and transferred to
polyvinylidene difluoride membranes. After overnight incu-
bation with primary antibodies at 4°C, each blot was probed
with horseradish peroxidase-conjugated secondary anti-
body. Immunoreactive signals were detected with an en-
hanced chemiluminescence substrate (Thermo Scientific)
using an AlphaEaseH FC Imaging System (Alpha Innotech
Corporation).
Protein translation arrest
HeLa cells were transfected with pEF1-FLAG-Tat in the
presence of 5 nM triptolide or vehicle (DMSO). After 28 h,
cells were treated with 20 μg/mL CHX to arrest protein
synthesis. Cells were harvested at 0, 1, 2, 3 h post-CHX
treatment and Western blotting was performed. FLAG-Tat
half-lives were determined as previously described [28].
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